Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) label expansion of 2 cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimens and approval of Lilly’s orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical problems, an indirect analysis comparing weight loss with oral semaglutide (Wegovy) versus orforglipron (Foundayo), new Clinical Practice Guidelines from the American Society of Hematology on the diagnosis and management of severe and very severe acquired aplastic anemia, and phase 3 VALOR trial data on brepocitinib in adults with dermatomyositis who had failed multiple prior treatments.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of March 29, 2026—let’s jump in!

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

On April 1, 2026, the FDA approved label expansions for a pair of CFTR modulator regimens, vanzacaftor/tezacaftor/ivacaftor (Alyftrek) and elexacaftor/tezacaftor/ivacaftor (Trikafta), broadening eligibility to an estimated 95% of people with CF in the United States. The expanded indications now encompass any 

 gene variant resulting in production of CFTR protein, in addition to variants previously identified as clinically or 

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

On April 1, 2026, the FDA approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, orforglipron helps individuals lose excess body weight and keep the weight off. In the ATTAIN-1 clinical trial, adults taking orforglipron lost an average of 27 pounds on the highest dose.

Of note, the once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist can be taken any time of the day without restrictions on food and water intake.

Indirect Analysis Suggests Greater Weight Loss With Oral Semaglutide vs Orforglipron

On April 2, 2026, Novo Nordisk announced a population-adjusted indirect comparison presented at the Obesity Medicine Association 2026 found greater mean weight loss with oral semaglutide (Wegovy) than with orforglipron (Foundayo) in adults with obesity or overweight and at least 1 weight-related comorbidity, both without diabetes. The analysis, which came the day following orforglipron’s FDA approval for obesity, also suggested lower odds of treatment discontinuation due to adverse events, particularly gastrointestinal events, with oral semaglutide.

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

The American Society of Hematology (ASH)’s new Clinical Practice Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia (AA) outline 33 recommendations and 4 good practice statements for children and adults. The document focuses on tools to improve diagnosis and treatment decisions, including expanded use of specialized blood and genetic tests, personalized initial treatment based on age and availability of a fully matched donor, the addition of eltrombopag to standard immunosuppressive therapy to improve blood cell counts, and earlier transition to second-line treatments after initial immunosuppression for patients who do not respond or relapse.

“It’s critical to definitively diagnose individuals with aplastic anemia to ensure that they are promptly connected to appropriate treatment,” said Phil Scheinberg, MD, head of the division of hematology at Hospital Beneficência Portuguesa Hospital in São Paulo, and chair of the ASH 2026 Guidelines for the Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia. “We hope these guidelines will not only improve patient outcomes but also expand access to diagnostic testing and catalyze broader global access to transplant and immunosuppressive therapies.”

VALOR: Brepocitinib AAD Data Support Priority Review for Dermatomyositis

Brepocitinib, an investigational oral therapy targeting TYK2 and JAK1 produced rapid, sustained improvements in global disease activity, skin disease, itch, and physical function in adults with dermatomyositis who had failed multiple prior treatments, prompting the FDA to grant the therapy Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of 2026. The new data from the phase 3 VALOR trial were published March 28, 2026, in the 

 and simultaneously presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting held in Denver, Colorado, from March 27-31.

Articles

Regulatory and clinical updates span cystic fibrosis, obesity pharmacotherapy, hematology, and autoimmune myositis. FDA expanded eligibility for two CFTR modulator regimens to variants producing CFTR protein, potentially covering ~95% of US cystic fibrosis patients. Lilly’s orforglipron became the first daily oral GLP-1RA without food/water restrictions for obesity or overweight with comorbidities, supported by ATTAIN-1 weight-loss data. Novo Nordisk reported an adjusted indirect comparison favoring oral semaglutide for efficacy and tolerability. ASH issued comprehensive severe aplastic anemia guidelines. Phase 3 VALOR data positioned brepocitinib for Priority Review in dermatomyositis.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hematology

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 03/29

Jane M. Grant-Kels, MD, is the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

A session titled ‘The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients’ was presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

One of the presenters of this session was Jane M. Grant-Kels, MD, the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

 interviewed Grant-Kels regarding some of the most important takeaways from this session. The following Q&A interview spotlights her responses:

Pregnancy presents a uniquely complex set of constraints for dermatologists such as limited evidence-based data and fetal safety concerns. In your view, what are the most common mistakes or gaps you see in how dermatologists currently approach the pregnant patient, and what does this session aim to address?

My area that I'm addressing is how to deal with melanocytic nevi and how to deal with melanoma. So during pregnancy, the woman's body changes. Obviously, her breasts enlarge, her abdomen enlarges, and melanocytic nevi on those locations can enlarge as well, but generally, melanocytic nevi do not change drastically during pregnancy. My advice is, if you have a melanocytic nevus and it's changing, you should check it with the dermatoscope, and if there are any changes that suggest malignancy, the lesion should be biopsied immediately.

Having said that, there's no suggestion that patients when pregnant have a higher incidence of developing melanoma. I also address the controversy about whether melanoma when it is developed during pregnancy has a worse prognosis, and that has been assumed in the past, because when women are pregnant, they are somewhat immunosuppressed. They have induced lymphangiogenesis and other angiogenesis…The evidence shows that when a woman is pregnant and if she does develop a melanoma, her prognosis is not different than if she were not pregnant. And so you treat them the same. So that is a sum of what I have to say to the audience.

Is there a general lack of clinical data, clinical trial data, regarding pregnant patients in the dermatology space, and is that the kind of thing that can be addressed?

 It's very hard to do studies on obstetricians don't like to share their pregnant patients for clinical trials, even if it's just observation and watching their moles. We did a study many years ago, and it took us a long time to get a significant number of pregnant women because it was very hard to induce obstetricians to refer patients, even though we were just examining their backs and their nevi on their backs. So yes, there is a paucity, and obviously clinical trials are very rarely done in pregnant women because of the fact that they're obviously they're carrying a fetus.

You wouldn't want to expose them to drugs unnecessarily, so that is an issue. And because of that, and because when a woman is pregnant and does develop a melanoma, especially if it's a high risk deep melanoma, those tend to get reported as case reports. So there are years of people under the false impression that pregnancy increased your risk of melanoma because of those case reports, when, in fact, when large studies are done looking at pregnant versus non pregnant women with control groups, there is no increased incidence of melanoma during pregnancy.

Among patients, are there concerns that you've seen among pregnant patients related to concerns such as these?

 Patients notice that their nevi on their breasts and abdomen change. They can see the those areas, and their skin gets enlarged, so the nevi get expanded. The pregnant women also develop some hyperpigmentation. Their areola, the nipple gets darker. They can develop a linear nigra, which is a hyperpigmentation on their abdomen in a vertical area, and so patients notice that there are changes in their skin. They get stretch marks, then patients get very nervous if you're going to inject a numbing medication to remove a lesion, because they always are concerned that it might hurt their baby. But there is very good evidence that to do a biopsy in a pregnant woman is perfectly safe.

Are there any other major takeaways from this session that you really hope clinicians walk away with?

 The big takeaway is that nevi don't change significantly physiologically during pregnancy. So if you have a nevus, if you have a patient who happens to be pregnant, and they're one of their nevi is changing. If you look at it with your dermatoscope and you see any features that suggest potential melanoma, you shouldn't assume those changes are physiologic. You should biopsy that patient, because just because they're pregnant doesn't mean they have an increased incidence of melanoma.

But it also doesn't mean they cannot get a melanoma because they can. There's an increased incidence of melanoma in women of childbearing age in general, that's unrelated to pregnancy, so the two can occur together. In the past, there was delay in diagnosis because many people felt that nevi changed physiologically during pregnancy. I would never make that assumption. If a nevus is changing and any features of malignancy are noted, take that lesion off. The other thing is, if you have a pregnant woman and she does develop a melanoma, you should educate her to the fact that her prognosis is not altered by her pregnancy. And especially if she has a relatively thin melanoma, she's going to do fine and it's not going to hurt her fetus.

The quotes contained in this summary were edited for clarity.

Grant-Kels J, et al. F001 The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients. Sesson presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Physiologic skin changes in pregnancy commonly prompt concern about evolving nevi, particularly on the breasts and abdomen as skin stretches and hyperpigmentation develops. However, melanocytic nevi typically do not change substantially during pregnancy; clinically significant change warrants dermoscopic assessment and prompt biopsy when malignant features are present. Available comparative data do not show increased melanoma incidence during pregnancy, and prognosis for pregnancy-associated melanoma appears comparable to nonpregnant patients when controlled analyses are used. Biopsy with local anesthesia is considered safe in pregnancy.

This Q&A interview with Grant-Kels highlights takeaways from her session on managing the needs of patients in dermatology practicers who are pregnant.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Advice for Evaluating Pregnant Patients in Dermatology, With Jane M. Grant-Kels, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

 approved Novo Nordisk’s insulin icodec-abae under the name Awiqli for patients with 

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlight the FDA approval of once-weekly insulin icodec, emphasizing its significance as a major advancement in insulin therapy. They begin by addressing practical considerations, including its high concentration (U-700) and the implications for dosing, noting that weekly administration necessitates substantially higher unit doses compared with daily basal insulin.

The discussion focuses on dosing strategy, particularly the need to scale weekly doses approximately sevenfold relative to daily regimens, as well as the rationale for an initial loading dose of 1.5 times the calculated weekly requirement to more rapidly achieve steady state. Isaacs underscores the pharmacokinetic basis for this approach, given the drug’s long half-life and delayed time to steady state, while also noting the constraints of dosing in 10-unit increments.

Bellini and Isaacs explore the clinical implications of once-weekly insulin, with particular attention to adherence and treatment burden. Bellini emphasizes the potential benefit for insulin-naive patients and those struggling with daily injection adherence, framing weekly insulin as a means to significantly reduce injection frequency and improve consistency. Isaacs expands on this, arguing that reduced dosing frequency may mitigate missed doses and glycemic variability, especially in patients with irregular routines. Both highlight the flexibility afforded by the long half-life, allowing for minor deviations in dosing timing without substantial impact on glycemic control.

The conversation also addresses potential risks, including delayed titration and the possibility of over-basalization, particularly in patients with fluctuating nutritional intake or socioeconomic instability. They stress the importance of careful patient selection and monitoring, given the longer interval required to adjust doses.

Reviewing clinical trial data from the ONWARDS phase 3 program, the hosts note that once-weekly insulin demonstrated modestly greater A1C reduction compared with daily basal insulin in treat-to-target trials, reinforcing the hypothesis that improved adherence may translate into better glycemic outcomes.

They further discuss implementation considerations across care settings, highlighting potential advantages for older adults, caregivers, and patients in long-term care, where reduced injection burden may improve safety, independence, and medication management. The episode also touches on current regulatory limitations, noting that while approval is presently limited to type 2 diabetes in the United States, ongoing studies may expand its indication to type 1 diabetes, with off-label use anticipated in select cases.

The hosts conclude by situating weekly insulin within the broader therapeutic landscape, emphasizing renewed innovation in insulin development alongside incretin-based therapies. They note that additional agents in development may soon expand options within this class, signaling a meaningful shift in the management of diabetes toward more patient-centered, lower-burden treatment paradigms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Novo Nordisk. Awiqli approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. March 26, 2026. Accessed April 3, 2026. 

https://ml-eu.globenewswire.com/Resource/Download/cb9dda59-1286-4718-a7e5-4256e2397b0c

Kunzmann K. FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. 

. March 26, 2026. Accessed April 3, 2026. 

https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes

Podcasts

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Videos

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mardi Gomberg-Maitland, MD, MSc, is the director of the pulmonary hypertension program, chief clinical research officer at the Office of Clinical Research SMHS, and a professor of medicine at George Washington University.

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc

Sotatercept has reduced pulmonary vascular resistance (PVR) in combined post- and pre-capillary pulmonary hypertension (CpcPH) 

heart failure with preserved ejection fraction (HFpEF)

, improving both pulmonary vascular and cardiac end points, according to data from the CADENCE trial.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by Mardi Gomberg-Maitland, MD, MSc, director of the pulmonary hypertension program, chief clinical research officer at the Office of Clinical Research SMHS, and professor of medicine at George Washington University.

“Here we have a drug for a disease that we’ve never had therapy for, one that has high morbidity and mortality, and now we have potential,” Gomberg-Maitland told 

 in an exclusive interview. “We’re seeing good effects – now it’s time that we move to the next phase, to phase 3.”

CADENCE is an ongoing phase 2, multicenter, double-blind, randomized trial investigating the efficacy, safety, and tolerability of sotatercept in patients with CpcPH-HFpEF. The trial consisted of a 24-week placebo-controlled treatment period and an active-drug extension period. Gomberg-Maitland and colleagues reported the placebo-controlled period, during which patients were randomly assigned in a 1:1:1 ratio to receive subcutaneous sotatercept at 0.3 mg/kg (before potential escalation to 0.7 mg/kg after 3 dosing visits) or placebo every 3 weeks.

Eligible patients were aged 18-85 years with symptomatic CpcPH-HFpEF diagnosed via an assessment of hemodynamics through right heart catheterization. Patients were excluded if they were diagnosed with another form of pulmonary hypertension, clinically significant lung disease, severe hepatic impairment, and/or cirrhosis, among other criteria.

CADENCE’s primary efficacy endpoint was the change from baseline in PVR at week 24. The key secondary efficacy endpoint was the change from baseline in 6-meter walk distance at week 24. Other secondary endpoints included time to clinical worsening, which was defined as the time from the first dose date to the first occurrence of all-cause death or non-elective hospitalization for cardiopulmonary indications related to pulmonary hypertension and/or heart failure, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, NYHA functional class, and hemodynamic or echocardiographic parameters.

A total of 164 patients were randomized, with 54 assigned to sotatercept 0.3 mg/kg, 55 assigned to 0.7 mg/kg escalated from 0.3, and 55 assigned to placebo. The median duration of follow-up during this period was 5.6 months (interquartile range [IQR], 5.5-5.7) in the 0.3 mg/kg group, 5.6 months (IQR, 5.5-5.8) in the 0.7 mg/kg group, and 5.6 months (IQR, 5.5-5.8) in the placebo group.

By week 24, sotatercept treatment resulted in substantially greater reductions in PVR versus placebo. The median change from baseline was -0.67 Wood units in the 0.3 mg/kg group, -0.33 Wood units in the 0.7 mg/kg group, and 0.26 Wood units in the placebo group. The Hodges-Lehmann shift estimate was -1.02 Wood units (95% CI, -1.81 to -0.23; 

 = .004) for the 0.3 mg/kg group and -0.75 Wood units (95% CI, -1.52 to 0.03; 

 = .024) for the 0.7 mg/kg group compared to placebo. These results were consistent across subgroups, including the degree of PVR elevation at baseline.

Mean pulmonary arterial pressure saw a mean reduction of -9.19 mmHg (95% CI, -13 to -5.38) and -9.22 (95% CI, -12.97 to -5.46) in the 0.3 mg/kg and 0.7 mg/kg groups, respectively. Changes in 6-minute walk distance were 20.3 meters (95% CI, 1.5 to 39.1) for the 0.3 mg/kg group and 5.8 meters (95% CI, -17.3 to 28.9) for the 0.7 mg/kg group.

Ultimately, Gomberg-Maitland and colleagues noted that these findings provide an effective proof of concept for improved pulmonary vascular and cardiac hemodynamics following activin signaling inhibition with sotatercept in patients with CpcPH-HFpEF.

“As for how it can impact therapy, we’re going to continue into our phase 3 trials to really look at these echo parameters over time and see if this is perhaps a way that we can follow patients,” Gomberg said. “Ultimately, you don’t want to be doing right heart casts on everybody to see how they’re doing. We need other assessments that are more functional.”

Editors’ Note: Gomberg-Maitland reports disclosures with Merck, Catalys Pacific, Gossamer, Janssen Pharmaceuticals, Medtronic, Novartis, and others.

Gomberg-Maitland M, Tedford R, Langleben D, et al. Efficacy and Safety of Sotatercept in Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: results from the Phase 2 Cadence Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, Louisiana. March 28-30, 2026.

Gomberg-Maitland M, Tedford RJ, Langleben D, et al. Sotatercept for combined post- and pre-capillary pulmonary hypertension associated with heart failure: Results from the phase 2, randomized, placebo-controlled Cadence Study. 

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD

Evidence shows a continually and rapidly expanding therapeutic landscape for patients with IgA nephropathy (IgAN). Due to the heterogeneity of the disease, clinicians remain undecided about how to approach these options with the IgAN’s complex, individualized presentation.

“It's getting more and more complicated with having more options out there, and we still have ongoing clinical trials, and we recruit for these trials as well. We have to keep in mind that we don't have a cure for IgAN yet, and we're not done with this field,” Norouzi siad. “I think the next step for a lot of our colleagues who are not spending a lot of time with IgAN patients would be a referral to a glomerular disease clinic or center of excellence.”

At WCN, a plethora of data supporting positive progress in IgAN was presented. In a

, Norouzi highlighted the emergence of targeted agents, including targeted-release budesonide, endothelin receptor antagonists like sparsentan and atrasentan, complement inhibitors such as iptacopan, and newer APRIL-targeting therapies. Together, these agents provide clinicians with multiple avenues to reduce proteinuria and preserve kidney function.

“When I go back from every conference that I attend to my clinic, my patients are excited. Sometimes I share with them that I'm going to a conference, and they know when I come back, I'm going to have more data, and they might have more options for their disease. And it's not just about IgAN. We're getting more options for C3G, lupus nephritis,” she concluded. “It's an exciting time to be a nephrologist.”

Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Arrhythmia

Cardiomyopathy

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Dyslipidemia

ACC 2026: Phase 2/3 Trials to Know

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

AAD 2026: 6 Psoriasis Trials to Know

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Catch up on the guideline updates, trial news, and featured content from March 2026. 


Chronic Kidney Disease

5 Nephrology Headlines You Missed in March 2026

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Diabetes Dialogue: 2026 AACE Guidelines for Type 2 Diabetes

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Q2 2026 Preview: 6 FDA Decisions to Watch

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Discussing Future of Amlitelimab, OX40/OX40L Treatment, With Eingun James Song, MD

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

AAD 2026: 6 Atopic Dermatitis Trials to Know

Future directions in ISM, including evolving treatment goals, unanswered questions about osteoporosis, anaphylaxis, resistance, curative strategies, and the need to extend advances to pediatric populations.

Video Series

Future Directions in ISM: Long-term Outcomes, Unanswered Questions, and Pediatric Considerations

Explore evolving colorectal cancer screening, from colonoscopy to advanced DNA/RNA stool tests, plus risk-based strategies and shared decisions that boost early detection.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 03/29

Advice for Evaluating Pregnant Patients in Dermatology, With Jane M. Grant-Kels, MD

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD